

Flow Cytometry in PNH: Clinical and Laboratory Perspectives

Louise Arnold, Advanced Practice Registered Nurse Daniel Payne, Consultant Clinical Scientist

PNH National Service St James's University Hospital Leeds, UK



Disclosures



- Consultancy and honoraria Daniel Payne
 - Sysmex
 - Novartis
 - AstraZeneca
- Consultancy and honoraria Louise Arnold
 - Novartis
 - Sobi
 - AstraZeneca / Alexion

Collaboration PNH National Service UK



- Early recognition
- Improved management
- Aligned data
- Effective communication




Accessed at pnhserviceuk.co.uk

PNH Flow Cytometry



- Set of standards
 - 1. Principles
 - 2. Reagent selection
 - 3. Sample preparation
 - 4. Flow cytometer setup
 - 5. Data analysis
 - 6. Reporting of results
 - 7. Ongoing verification
- Audit local practice for compliance



Sutherland et al 2018 Cytometry Part B: Clinical Cytometry





- May 2003
 - Initial symptoms occurred
 - 2 hospital admissions over the year
- August 2004
 - Black urine, Dysphagia, Jaundice
 - LDH 3263 IU/L (13xULN)
 - HB 70g/L, platelets 50 x10*9/L
 - Erythrocyte transfusions
 - Folic acid & ferrous sulphate
- December 2004
 - Blood sample sent for PNH testing




Identification of PNH White Blood Cell












- Neutrophil PNH clone 68.4%
- Confirmed diagnosis of PNH

- Red cell PNH clone 13.23%
 - 12.44% type III cells & 0.79% type II cells




- September 2005 Eculizumab
- June 2021 Ravulizumab
 - LDH 224 IU/L
- September 2016 to 2025
 - Large PNH Clone 99%
 - Hb 132g/L
 - Platelets 51 x10*9/L
 - LDH 350 IU/L






- 2006
 - Severe Aplastic Anemia
 - ATG + cyclosporine
 - Full recovery
- 2014-2015
 - Pregnant
 - Fall in counts
 - Cyclosporine
 - Eculizumab







- 2017-2021
 - Patient's condition stable
 - Maintaining good quality of life


What is important?


















Important Considerations in Aplastic Anemia



- Monitor the PNH clone at least annually
- If the clone is increasing or decreasing or other symptoms / change in results
 - More frequent reviews
- Consider investigations
- Adjust therapy depending on all results and symptoms
- Close monitoring and discussion




- 1997 Aplastic Anemia
- 2001 Large PNH clone
- 2002 Eculizumab
- 2006-2018
 - Erythrocyte transfusions
 - Why is the graph so busy?




Assessment of Extravascular Hemolysis (C3d on PNH RBC)






Assessment of Extravascular Hemolysis (hemoglobin)








- 2019
 - Commenced Proximal Complement Inhibition (PCI)
- Received intermittent venesections



From Early Results to Modern Diagnostics





- PNH neutrophils & red cell clone
- Start of complement inhibition in PNH
- Impact on QoL

- Extravascular hemolysis
- Proximal complement inhibition
- PK/PD assays
- CH50 on eculizumab

- Additionally able to evaluate PNH reticulocytes cell clone & C3d loading
- Individualised patient care
- Focus on improving morbidity & mortality

Going With The Flow



- Check laboratory is performing external quality assurance / sample sharing / part of a network
- Discuss and question unusual / atypical results
- Ask for advice, speak to PNH experts
- Work together with your laboratory
 - Appropriate alerts and pathways in place for new patients
 - Useful tools graphs, assessing immature red cells/reticulocytes



THANK YOU!